Duchenne muscular dystrophy

Pharma News for Sarepta and Ionis
Bristol-Myers Squibb’s Opdivo & Yervoy Combo Trial; Sarepta’s Gene Therapy SRP-9001 for DMD;...

Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adj...


Gene-Therapy-in-the-Duchenne-Muscular-Dystrophy-Treatment-Market
What Does the Future Hold For Gene Therapy in the Duchenne Muscular Dystrophy (DMD) Treatment Mar...

Duchenne Muscular Dystrophy (DMD) is a rare disorder, but it is one of the most common genetic conditions, affecting roughly 1 in every 3,500 male births worldwide. It is usually observed between ...


Fda-Approved-Top-Drugs-Launched-in-2021
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of...

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceut...


pharma-biotech-news-updates-for-pfizer-kytopen-eli-lilly-vensana-reify-health
Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reif...

Pfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase...


duchenne-muscular-dystrophy-market-size-share-trends-companies-cagr-growth-therapy-treatment-therapeutics
Duchenne Muscular Dystrophy Market: What’s More Beyond Exon-Skipping Therapies?

Duchenne muscular dystrophy (DMD) is a rare genetic disorder usually diagnosed in young boys, gradually weakening muscles across the body until the heart or lungs fail. Symptoms often show up by t...


pharma news
Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval

Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation.  Duchenne Muscular Dystrophy is...


Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspater...


Pharma News
Juvenescence nets USD 100M; Sarepta DMD drug faces rejection

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The...


transthyretin amyloidosis
Notizia

Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Admi...


FDA Approves Sarepta’s Muscular Dystrophy Drug after Months of Debate

The Food and Drug Administration approved the recent controversial drug to treat Duchenne muscular Dystrophy, which is a rare disease that confines boys to wheelchairs and condemns them to an early...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.